Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Pain 1Neoplasm, Residual 1Multiple Myeloma 1Dwarfism, Pituitary 1Disease Progression 1Breast Neoplasms 1Bone Diseases, Metabolic 1

Interventions

umbralisib 1ublituximab 1marizomib 1fludarabine phosphate 1fludarabine 1enzastaurin 1durvalumab 1carotuximab 1brigatinib 1binimetinib 1axicabtagene ciloleucel 1Zoledronic Acid 1Vitamin D 1Receptors, Interleukin-6 1Oxaliplatin 1Leucovorin 1Irinotecan 1Interleukin 1 Receptor Antagonist Protein 1Gemcitabine 1Folfox protocol 1Fluorouracil 1Cyclophosphamide 1Cisplatin 1Calcium 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Disease Progression × Calcium × Clear all
NCT00171925 2012-04-11

Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I

Novartis

Phase 3 Terminated
143 enrolled 10 charts
Plasma cell

Multiple Myeloma, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡